Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir.
After external beam radiation therapy, pretreatment prostate-specific antigen (PSA) is the most powerful predictor of outcome as measured PSA (biochemical) failure. The post-treatment nadir levels of PSA that predict best for subsequent freedom from PSA failure are debatable, and many nadir levels have been proposed as targets. Although lower nadirs generally are associated with superior outcomes, the identification of a single absolute nadir level was not selected at a recent ASTRO consensus conference. Rather, three consecutive PSA rises above the nadir, with date of failure at the midpoint between the nadir and first rise, were selected as a more useful end point for treatment failure.
Schellhammer
P F
PF
Department of Urology, Virginia Prostate Center, Eastern Virginia Medical School, Norfolk, USA.
el-Mahdi
A M
AM
Kuban
D A
DA
Wright
G L
GL
D000368:Aged; D006801:Humans; D008297:Male; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000532:radiotherapy*
D017430:Prostate-Specific Antigen